Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis.

ABSTRACT:

Rational & objective

Data are limited regarding the long-term efficacy of tolvaptan in adults aged 18-35 years with autosomal dominant polycystic kidney disease (ADPKD) at increased risk of rapid progression. We assessed the effects of tolvaptan within a larger population of younger adults and over longer follow-up than individual clinical trials could provide.

Study design

Pooled database study.

Setting & study populations

A consolidated clinical study database with ADPKD patients aged 18-35 years.

Selection criteria for studies

Studies that enrolled patients who received either tolvaptan or standard-of-care treatment not including tolvaptan.

Data extraction

Annual rate of change in estimated glomerular filtration rate (eGFR) and time to kidney failure.

SUBMITTER: Chebib FT 

PROVIDER: S-EPMC11731472 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature